Cargando…

Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern

SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Jia Ming, Gu, Yue, Ng, Melissa Shu Feng, Wang, Liang Wei, Amin, Zubair, Zhong, Youjia, MacAry, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880232/
https://www.ncbi.nlm.nih.gov/pubmed/35214683
http://dx.doi.org/10.3390/vaccines10020225
_version_ 1784659136170950656
author Low, Jia Ming
Gu, Yue
Ng, Melissa Shu Feng
Wang, Liang Wei
Amin, Zubair
Zhong, Youjia
MacAry, Paul A.
author_facet Low, Jia Ming
Gu, Yue
Ng, Melissa Shu Feng
Wang, Liang Wei
Amin, Zubair
Zhong, Youjia
MacAry, Paul A.
author_sort Low, Jia Ming
collection PubMed
description SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity transferred from breastfeeding mothers to their infants. In this study, we collected milk samples at three different time points pre- and post-vaccination, and measured milk IgA antibody binding to the receptor binding domain (RBD) of the original Wuhan-Hu-1 strain, and the four VOCs, namely Alpha, Beta, Gamma and Delta. We report a significant level of anti-RBD IgA in milk collected at 4–6 weeks after the second dose of vaccination compared to pre-vaccination. We observed around a 30% reduction in binding to most VOCs, including the major circulating Delta variant, compared to the original Wuhan-Hu-1 strain. As COVID-19 vaccines may take some time to be approved for infants, these individuals remain at risk for severe disease and rely mainly on transferred passive immunity. Our findings support the current recommendations for vaccinating lactating women with the aim of transferring mucosal immunity to breastfeeding infants.
format Online
Article
Text
id pubmed-8880232
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88802322022-02-26 Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern Low, Jia Ming Gu, Yue Ng, Melissa Shu Feng Wang, Liang Wei Amin, Zubair Zhong, Youjia MacAry, Paul A. Vaccines (Basel) Article SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity transferred from breastfeeding mothers to their infants. In this study, we collected milk samples at three different time points pre- and post-vaccination, and measured milk IgA antibody binding to the receptor binding domain (RBD) of the original Wuhan-Hu-1 strain, and the four VOCs, namely Alpha, Beta, Gamma and Delta. We report a significant level of anti-RBD IgA in milk collected at 4–6 weeks after the second dose of vaccination compared to pre-vaccination. We observed around a 30% reduction in binding to most VOCs, including the major circulating Delta variant, compared to the original Wuhan-Hu-1 strain. As COVID-19 vaccines may take some time to be approved for infants, these individuals remain at risk for severe disease and rely mainly on transferred passive immunity. Our findings support the current recommendations for vaccinating lactating women with the aim of transferring mucosal immunity to breastfeeding infants. MDPI 2022-01-31 /pmc/articles/PMC8880232/ /pubmed/35214683 http://dx.doi.org/10.3390/vaccines10020225 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Low, Jia Ming
Gu, Yue
Ng, Melissa Shu Feng
Wang, Liang Wei
Amin, Zubair
Zhong, Youjia
MacAry, Paul A.
Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
title Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
title_full Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
title_fullStr Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
title_full_unstemmed Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
title_short Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
title_sort human milk antibodies after bnt162b2 vaccination exhibit reduced binding against sars-cov-2 variants of concern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880232/
https://www.ncbi.nlm.nih.gov/pubmed/35214683
http://dx.doi.org/10.3390/vaccines10020225
work_keys_str_mv AT lowjiaming humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern
AT guyue humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern
AT ngmelissashufeng humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern
AT wangliangwei humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern
AT aminzubair humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern
AT zhongyoujia humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern
AT macarypaula humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern